Institutional Ownership
Vistagen Therapeutics Inc
CUSIP 92840H400COMVTGNQ1 2026
13D / 13G Filings
34
Schedule 13D/13G on record
Beneficial Filers
15
Distinct reporting persons
Largest Stake
19.7%
Max % of class reported
Institutional Holders
53
13F filers (latest quarter)
Beneficial Owners — Schedule 13D / 13G
34 filings · latest Feb 17, 2026
| # | Filed | Reporting Person | Form | % of Class | Shares | Filing |
|---|---|---|---|---|---|---|
| 1 | Feb 17, 2026 | Commodore Capital LP | 13G/A | 11.0% | 4.38M | SEC |
| 2 | Feb 17, 2026 | Janus Henderson Group PLC | 13G/A | — | — | SEC |
| 3 | Feb 17, 2026 | Great Point Partners, LLC | 13G/A | 5.0% | 2.06M | SEC |
| 4 | Feb 17, 2026 | Stempoint Capital LP | 13G/A | 1.5% | 616.7K | SEC |
| 5 | Feb 17, 2026 | Orbimed Advisors LLC | 13G/A | 4.2% | 14.20T | SEC |
| 6 | Feb 13, 2026 | Nantahala Capital Management, LLC | 13G/A | 4.7% | 1.95M | SEC |
| 7 | Jan 30, 2026 | The Vanguard Group | 13G/A | 4.6% | 1.82M | SEC |
| 8 | Nov 14, 2025 | Great Point Partners, LLC | 13G/A | 6.3% | 2.06M | SEC |
| 9 | Nov 14, 2025 | Nantahala Capital Management, LLC | 13G/A | 10.0% | 3.19M | SEC |
| 10 | Nov 14, 2025 | Orbimed Advisors LLC | 13G | 5.3% | 14.20T | SEC |
24 more beneficial-ownership filings on Premium
See the full Schedule 13D/13G history for Vistagen Therapeutics Inc.
Unlock full historyTop Institutional Holders (13F)
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Orbimed Advisors LLC | 3.06M | $1.75M |
| 2 | Tcg Crossover Management, LLC | 2.68M | $1.53M |
| 3 | Adar1 Capital Management, LLC | 751.1K | $429.3K |
| 4 | Ikarian Capital, LLC | 519.1K | $296.7K |
| 5 | Two Sigma Investments, LP | 469.6K | $268.4K |
| 6 | Geode Capital Management, LLC | 453.4K | $259.2K |
| 7 | Blackrock, Inc. | 448.5K | $256.3K |
| 8 | Millennium Management LLC | 430.4K | $246.0K |
| 9 | Luminus Management LLC | 396.1K | $226.3K |
| 10 | Renaissance Technologies LLC | 291.3K | $166.5K |